Kobayashi Pharma schedules November 10 results for Kobayashi Pharma stock

Published on 10/20/2026 at 20:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit JPY 37.08 billion while net income was JPY 100.00 million. Kobayashi Pharma stock costs EUR 40.90 on October 20, 2026.

Earnings and valuation facts

Kobayashi Pharma has its next earnings date scheduled for November 10, 2026.
Revenue reached JPY 37.08 billion and net income was JPY 100.00 million in the second quarter of fiscal 2026.
Kobayashi Pharma stock cost EUR 40.90 at Lang & Schwarz on October 20, 2026 at 8:13 p.m. CEST.
The Tokyo listing closed at JPY 7,223.00 on October 20, 2026, while market capitalization stood at JPY 536.9 billion.

Kobayashi Pharma, JP3301100008, Illustration mit AI erstellt.

Kobayashi Pharma (ISIN JP3301100008) has its next earnings date scheduled for November 10, 2026, according to Finranks. The company reported JPY 37.08 billion in revenue and JPY 100.00 million in net income for the second quarter of fiscal 2026, figures also carried by Investing.com. Kobayashi Pharma was trading at EUR 40.90 at Lang & Schwarz on October 20, 2026 at 8:13 p.m. CEST.

Second-quarter earnings remain the focus

The June 30, 2026 quarter produced operating income of JPY 811.00 million and earnings per share of JPY 1.35. The preceding quarter had delivered operating income of JPY 1.35 billion and net income of JPY 1.04 billion, so the latest figures show a lower profit contribution despite higher revenue.

The six-month results were dated August 6, 2026 in the company coverage listed by 6ix. The next scheduled reporting date gives investors a defined calendar point for comparing the third-quarter figures with the first half of fiscal 2026.

Tokyo price stays near its yearly high

On the Tokyo Stock Exchange, Kobayashi Pharma closed at JPY 7,223.00 on October 20, 2026 at 3:30 p.m. JST, down 0.15 percent from the previous close. The same session traded between JPY 7,223.00 and JPY 7,293.00, while the 52-week range ran from JPY 5,030.00 to JPY 7,388.00.

That closing level was 2.23 percent below the 52-week high. Trading volume reached 170,400 shares, and the market capitalization was JPY 536.9 billion. The valuation remains elevated against the reported earnings base, with a price-to-earnings ratio of 330.27.

Comparison with peers

Kobayashi Pharma: price-to-earnings ratio 330.27, market capitalization JPY 536.9 billion. Sumitomo Pharma (Tokyo, JPY): up 0.83 percent, price-to-earnings ratio 6.74, market capitalization JPY 846.0 billion. Santen Pharmaceutical (Tokyo, JPY): up 0.06 percent, price-to-earnings ratio 14.54, market capitalization JPY 555.0 billion.

November date sets the next checkpoint

The November 10, 2026 earnings date is the next scheduled corporate event. Until then, the main numerical contrast is between revenue of JPY 37.08 billion in the second quarter and net income of JPY 100.00 million, alongside a Tokyo valuation of JPY 536.9 billion.

The stock was trading at EUR 40.90 at Lang & Schwarz on October 20, 2026 at 8:13 p.m. CEST. The Tokyo listing had closed at JPY 7,223.00 on October 20, 2026 at 3:30 p.m. JST. The further course of trading is shown by the continuously updated real-time quote of Kobayashi Pharma stock.